NasdaqGS - Nasdaq Real Time Price USD

Pacific Biosciences of California, Inc. (PACB)

Compare

1.6400

+0.0400

+(2.50%)

At close: January 17 at 4:00:01 PM EST

1.6503

+0.01

+(0.63%)

After hours: 7:57:51 PM EST

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks yesterday

PACB
+2.50%
INSP
PACB Stock Declines Despite Promising HiFi Sequencing Findings

PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.

Zacks 2 days ago

PACB
+2.50%
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped

PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.

Zacks 2 days ago

PACB
+2.50%
ABT
PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics. The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple di

GlobeNewswire 3 days ago

PACB
+2.50%
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154.0 million representing a year-over-year de

GlobeNewswire 3 days ago

PACB
+2.50%
PacBio Stock May Gain Following the Collaborated Launch of GutID

PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.

Zacks 4 days ago

PACB
+2.50%
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics

PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.

Zacks 7 days ago

PACB
+2.50%
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By combining Intus Bio’s patented strain-level resolution assay and AI-powered analysis with PacBio’s renowned sequencing accuracy, GutI

GlobeNewswire 7 days ago

PACB
+2.50%
PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets

Berry Genomics will leverage PacBio Vega System to develop long-read sequencing-based solutions for patients in China and other countriesMENLO PARK, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, has delivered its first Vega systems to Berry Genomics as part of an early access agreement announced in 2022. Under the terms of the original agreement, Berry Genomics will develop and optimize its targeted assays to supp

GlobeNewswire 9 days ago

PACB
+2.50%
Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today

Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0.5% move from the prior day.

Zacks 10 days ago

PACB
+2.50%
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

With Ark Invest ending 2024 on a strong note, the aggressive growth icon is hoping to build on that momentum in 2025.

Motley Fool 10 days ago

AMZN

GTLB

PACB
+2.50%
PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for

GlobeNewswire 15 days ago

PACB
+2.50%
Why Is Pacific Biosciences of California, Inc. (PACB) Among the Top CRISPR Stocks to Invest In?

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, […]

Insider Monkey 18 days ago

PACB
+2.50%
Reasons to Retain PacBio Stock in Your Portfolio for Now

PACB continues to deliver growth from its unique technologies amid business seasonality concerns.

Zacks last month

PACB
+2.50%
GMED
Why Pacific Biosciences of California (PACB) Is the Worst ARK Stock to Buy According to Short Sellers

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street’s most […]

Insider Monkey last month

PACB
+2.50%
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in […]

Insider Monkey last month

PACB
+2.50%
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Pacific Biosciences of California ( NASDAQ:PACB ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.0m...

Simply Wall St. 2 months ago

PACB
+2.50%
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Last week, you might have seen that Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) released its third-quarter...

Simply Wall St. 2 months ago

PACB
+2.50%
PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 5:00 PM ET in Rancho Palos Verdes, CAWolfe Research Healthcare Conference on Tuesday, November 19, 2024, at 3:30 PM ET in New York, NYStephens Annual Investment Conference on We

GlobeNewswire 2 months ago

PACB
+2.50%
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y

PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.

Zacks 2 months ago

PACB
+2.50%
DGX

Performance Overview

Return	PACB	S&P 500
YTD	-8.38%	+1.52%
1-Year	-74.45%	+25.82%
3-Year	-86.81%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pacific Biosciences of California, Inc. (PACB)

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

PACB Stock Declines Despite Promising HiFi Sequencing Findings

PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

PacBio Stock May Gain Following the Collaborated Launch of GutID

PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics

PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets

Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

Why Is Pacific Biosciences of California, Inc. (PACB) Among the Top CRISPR Stocks to Invest In?

Reasons to Retain PacBio Stock in Your Portfolio for Now

Why Pacific Biosciences of California (PACB) Is the Worst ARK Stock to Buy According to Short Sellers

Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now

Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

PacBio to Present at Upcoming Investor Conferences

PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y

Performance Overview